CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 156	$ 967
Operating expenses:
Research and development	31,661	26,798
General and administrative	9,103	6,640
Total operating expenses	40,764	33,438
Operating loss	(40,608)	(32,471)
Investment and other income, net	7,800	3,110
Net loss	$ (32,808)	$ (29,361)
Basic net loss per common share (in dollars per share)	$ (0.56)	$ (0.62)
Diluted net loss per common share (in dollars per share)	$ (0.56)	$ (0.62)
Shares used in calculating basic net loss per share (in shares)	58,871	47,214
Shares used in calculating diluted net loss per share (in shares)	58,871	47,214
Comprehensive loss:
Net loss	$ (32,808)	$ (29,361)
Other comprehensive income (loss):
Unrealized (loss) gain on marketable securities	(1,064)	863
Comprehensive loss	(33,872)	(28,498)
Product development and licensing agreements
Revenues:
Total revenues	2
Contracts and grants
Revenues:
Total revenues	$ 154	$ 967